UBC Study Shows Psychedelic Drug Microdoses Show Promise Against Mental Illnesses

Psychedelic substances have been used for centuries among the pre-Columbian Aztec and Mayan societies as well as indigenous peoples of the Americas, which include the Huichol and the Mazatec. The use of smaller doses of psychedelics in societies such as the Mazatec people to support the healing of various physical conditions is common despite scanty documentation on it.

Microdosing refers to the practice of consuming small doses of a psychedelic substance to benefit from it while minimizing the drug’s undesirable side effects. For years, researchers have conducted studies on psychedelic microdosing in order to learn its benefits, with a recent global study led by the Okanagan campus at the University of British Columbia finding that small doses of psychedelic substances may be useful in the treatment of mental health conditions.

For their study, the researchers recruited more than 8,000 participants through a mobile application, 4,050 of whom had microdosed on psychedelics.

The study’s findings show that grownups who consumed daily microdoses of psilocybin or LSD displayed fewer symptoms of depression and anxiety, in comparison with adults who didn’t. The researchers also found that the individuals who microdosed also reported greater feelings of well-being.

In a news release, Joseph Rootman, a doctoral student at UBC Okanagan and the lead author of the study, stated that there was a clear link between less symptoms of stress, anxiety and depression and microdosing of psychedelic substances, which is crucial given the epidemic of mental health issues and the considerable suffering they cause.

Psilocybin mushrooms were the most commonly used substances, with researchers noting that participants reported different practices, frequencies and dosages. These practices included stacking, which is combining the use of magic mushrooms with nonpsychedelic substances such as lion’s mane mushrooms, niacin and chocolate.

This research is the first to comprehensively study stacking, according to scientists at the University of British Columbia. A psychology professor at the institution, Dr. Zach Walsh, stated that current treatments weren’t effective for every individual, and given the prevalence of mental health conditions, it was important for researchers to follow the lead of patients who were taking the initiative to reduce their suffering and improve their well-being.

In the study, the researchers reported that wellness and health were the leading motivations for participants who engaged in microdosing, noting that this was even more prominent in women with mental health conditions.

The study’s authors note that the research highlights the need for more studies on the consequences of microdosing and mental health, including studies with detailed longitudinal designs.

Plenty of research is currently ongoing to get a better understanding of psychedelics and their effects, and entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are focused on developing mental health treatments from these substances.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.